Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Lung, Respiratory and Thoracic Cancer

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Oncol Ther

Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N

doi: 10.1007/s40487-026-00437-8

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Lung Cancer

Zhang C, Wang W, Bi N, Wang J, Liu W, Zhang T, Wang X, Xiao Z, Lv J, Feng Q, Deng L, Zhou Z

doi: 10.1016/j.lungcan.2025.108758

Lung, Respiratory and Thoracic Cancer

Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England

Lung Cancer

Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B

doi: 10.1016/j.lungcan.2026.109469

Lung, Respiratory and Thoracic Cancer

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

J Thorac Oncol

Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ

doi: 10.1016/j.jtho.2026.103651

Lung, Respiratory and Thoracic Cancer

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

Oncol Ther

Godbert B, Gobbini E, Decroisette C, Lena H, Khalife Y, Brellier F, Fleuriet A, Zysman M, Egenod T, Moro Sibilot D, Girard N

doi: 10.1007/s40487-025-00381-z

Lung, Respiratory and Thoracic Cancer

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Lung Cancer

Uehara Y, Ikegami M, Kohsaka S, Kimura H, Mizushima M, Okuma Y

doi: 10.1016/j.lungcan.2026.109491

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur J Cancer

Gemelli M, Sala L, Morabito A, Sforza V, Cortellini A, La Cava G, Bertolini F, Guaitoli G, Carnio S, Novello S, Leonetti A, Tiseo M, Mazzoni F, Cosso F, Macerelli M, Membrino A, Metro G, Chiari R, Genova C, Berardi R, Tassistro E, Antolini L, Cortinovis DL

doi: 10.1016/j.ejca.2026.116579

Related content

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study

Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study